文献类型：期刊文献

中文题名：牡蛎肽对高脂饮食小鼠的血脂异常和动脉粥样硬化的影响及其机制

英文题名：Effect and Mechanism of Oyster-Derived Peptides on Hyperlipidemia and Atherosclerosis in High-Fat Diet-Fed Mice

作者：张烘煜[1];王禹鸥[1];陈忠琴[1,2,3,4];谭明堂[1,2,3,4];陈铭[1,2,3,4];高加龙[1,2,3,4];郑惠娜[1,2,3,4];林海生[1,2,3,4];曹文红[1,2,3,4]

机构：[1]广东海洋大学食品科技学院,广东湛江524088;[2]国家贝类加工技术研发分中心,广东湛江524088;[3]广东省海洋食品工程技术研究中心,广东湛江524088;[4]广东省水产品加工与安全重点实验室,广东湛江524088

年份：2026

卷号：46

期号：1

起止页码：139

中文期刊名：广东海洋大学学报

外文期刊名：Journal of Guangdong Ocean University

收录：北大核心2023、、北大核心

基金：国家现代农业产业技术体系项目(CARS-49);广东省现代农业技术体系贝类藻类产业创新团队项目(2024CXTD23)。

语种：中文

中文关键词：牡蛎肽;胆固醇代谢;降胆固醇肽;分子机制;肠道微生物群

外文关键词：oyster peptide;cholesterol metabolism;cholesterol-lowering peptides;molecular mechanisms;gut microbiota

中文摘要：【目的】探究牡蛎(Ostreidae)衍生肽(OPs)对高脂饮食(HFD)诱导小鼠代谢综合征的改善作用及机制,为牡蛎肽功能性食品开发提供依据。【方法】雄性C57BL/6小鼠经高脂饲料喂养16周,分别灌胃给予低、中、高剂量粗提牡蛎肽[400、800、1200 mg/(kg·d^(-1)),OP]或纯化牡蛎肽[400、500、600 mg/(kg·d^(-1)),OPP],以正常饮食小鼠为空白对照,高脂饮食小鼠为模型对照,市售保健品300 mg/(kg·d^(-1))及依折麦布辛伐他汀20 mg/(kg·d^(-1))为阳性对照。通过测定体质量,脏器指数,血清血脂水平,肝脏胆固醇代谢关键蛋白表达及相关基因转录水平,肝脏、脂肪组织及主动脉病理形态,肠道菌群16S rRNA多样性及组成结测指标,分析牡蛎肽对HFD诱导小鼠代谢综合征的影响,解析其作用机制。【结果】与模型组相比,OP与OPP均呈剂量依赖性地显著抑制HFD诱导的小鼠代谢紊乱:高剂量纯化牡蛎肽(OPP-H,600 mg/kg)使体质量增幅降低32%,血清总胆固醇(TC)、总甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)分别下降29%、35%、33%,高密度脂蛋白胆固醇(HDL-C)降低18%,且均差异显著(P<0.01);肝脏脂质沉积面积减少47%(从47%降至25%),脂肪细胞平均面积缩小35%(从11500μm^(2)降至7500μm^(2)),主动脉斑块面积减少40%(从25%降至15%)。蛋白与基因表达分析显示,OP与OPP可下调肠道胆固醇吸收转运蛋白NPC1L1与肝脏胆固醇合成限速酶HMGCR的表达(分别降低4.4%和5.0%),同时上调胆固醇分解关键酶基因CYP7A1及其转录调控因子基因PXR的表达(分别升高12.9%和18.8%),提示其对胆固醇吸收、合成与分解代谢的多重调节作用。此外,16S rRNA测序分析发现,OPP-H组肠道菌群Chao 1和Shannon指数较模型组分别回升31%和24%,乳酸杆菌(Lactobacillus)与双歧杆菌(Bifidobacterium)相对丰度增加2.3倍和1.9倍。【结论】牡蛎肽(特别是纯化牡蛎肽)通过协同调节宿主胆固醇代谢通路与肠道微生物群,缓解HFD诱导的代谢紊乱,展现出其作为功能食品基料应用于心血管健康的巨大潜力。

外文摘要：【Objective】To investigate the ameliorative effects and mechanism of oyster(Ostreidae)-derived peptides(OPs)on high-fat diet(HFD)-induced metabolic syndrome in mice,and to provide a basis for the development of oyster peptide-based functional foods.【Methods】Male C57BL/6 mice were fed with a high-fat diet for 16 weeks and orally administered low,medium,and high doses of crude oyster peptide[OP;400,800,1200 mg/(kg·d^(-1))]or purified oyster peptide[OPP;400,500,600 mg/(kg·d^(-1))],respectively.Mice fed a normal diet served as the blank control,those fed a high-fat diet served as the model control,and those treated with a commercial health product[300 mg/(kg·d^(-1))]or ezetimibe/simvastatin[20 mg/(kg·d^(-1))]served as positive controls.The effects of OPs on HFD-induced metabolic syndrome in mice and the underlying mechanisms were analyzed by measuring body mass,organ indices,serum lipid levels,protein expression of key regulators involved in hepatic cholesterol metabolism and transcriptional levels of related genes,pathological morphology of the liver,adipose tissue,and aorta,as well as 16S rRNA diversity and compositional structure of the gut microbiota.【Results】Compared with the model group,both OP and OPP dose-dependently and significantly inhibited HFD-induced metabolic disorders in mice.Specifically,high-dose purified oyster peptide(OPP-H,600 mg/kg)reduced body mass gain by 32%;decreased serum total cholesterol(TC),total glyceride(TG),and low-density lipoprotein cholesterol(LDL-C)by 29%,35%,and 33%,respectively;and lowered high-density lipoprotein cholesterol(HDL-C)by 18%,with all changes showing significant differences(P<0.01).Furthermore,it reduced the area of hepatic lipid deposition by 47%(from 47%to 25%),decreased the average adipocyte area by 35%(from 11500μm^(2)to 7500μm^(2)),and diminished the aortic plaque area by 40%(from 25%to 15%).Protein and gene expression analyses revealed that OP and OPP downregulated the intestinal cholesterol transporter NPC1L1 and the hepatic cholesterol synthesis rate-limiting enzyme HMGCR(by 4.4%and 5.0%,respectively),while upregulating the expression of the genes of key cholesterol-catabolizing enzyme CYP7A1 and its transcriptional regulator PXR(by 12.9%and 18.8%,respectively),suggesting a multi-target regulatory effect on cholesterol absorption,synthesis,and catabolism.Additionally,16S rRNA sequencing analysis showed that,compared with the model group,the OPP-H group exhibited a 31%and 24%increase in the Chao1 and Shannon indices of the gut microbiota,respectively,along with a 2.3-fold and 1.9-fold increase in the relative abundance of Lactobacillus and Bifidobacterium.【Conclusion】Oyster peptides,particularly the purified form,alleviate HFD-induced metabolic dysregulation by synergistically modulating host cholesterol metabolic pathways and the gut microbiota,demonstrating their significant potential as functional food ingredients for cardiovascular health.